Strategic M&A momentum Immedica Pharma US Inc. merged with Marinus in 2025 to expand footprint and capabilities, signaling openness to partnerships and potential channel expansion, co-development, or distribution opportunities in new markets.

Licensing and royalty potential Existing exclusive patent license with Ovid Therapeutics for ganaxolone in CDKL5 deficiency disorder creates opportunities to cross-sell or co-market related therapies, and to approach similar partners for expanded indications or regional licensing deals.

European commercialization Orion Corporation secured exclusive European rights for ganaxolone, highlighting a path for regional partnerships or secondary licensing deals in Europe, and potential collaboration on market access and reimbursement strategies.

Clinical and regulatory signals Recent trial setbacks and investor legal actions indicate heightened risk but also a potential need for strategic governance, independent clinical advisory partnerships, and accelerated programs in alternative trials or indications to de-risk the portfolio.

Financial and funding posture substantial funding ($452M) and moderate revenue ($10–$25M) position Marinus for strategic investments in clinical development, manufacturing scale-up, and partnerships with larger biopharma to broaden commercialization and reduce time-to-market.